US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Boehringer Ingelheim

< Previous 1 2 Next >
News headline image
Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Boehringer Ingelheim investments into sustainability-related programs and health partnerships to reach EUR 500 million
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Boehringer Ingelheim and AWARE launch new Stop Rabies project in Zimbabwe to help protect dogs and communities
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Boehringer Ingelheim launches PED Essentials, an online learning resource that gives patients a stronger voice
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Boehringer Ingelheim launches SCOVELLA® in Great Britain, the first approved therapy for insulin dysregulation in horses, a main cause of laminitis
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Boehringer Ingelheim expands equine health pipeline with acquisition of Evax AG
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product launches in the U.S.
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Boehringer Ingelheim Launches Swine Vaccine With Advanced Protection Against Porcine Circovirus Type 2 in the United States
From Boehringer Ingelheim
Via Business Wire
News headline image
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Boehringer Ingelheim expands cancer research at its Vienna site
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Boehringer Ingelheim produces its own green energy
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Less than half of veterinary professionals feel their profession is appreciated
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
SPEVIGO® approved for expanded indications in China and the US
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
New collaboration between Boehringer Ingelheim and Sleip leverages AI-technology to help detect lameness in horses
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Boehringer expands production site in Greece for new medicine
From Boehringer Ingelheim
Via GlobeNewswire
News headline image
Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats
From Boehringer Ingelheim
Via Business Wire
News headline image
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
From Boehringer Ingelheim
Via Business Wire
< Previous 1 2 Next >